Develops synthetic allogeneic iMSC cell therapies.
Dec 2024Revenue $582K/yrExpenses $16.3M/yr
No trend
Figures by year
When will Ernexa Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was $582K and expenses $16.3M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $582K | $16.3M | −$15.7M |
| Dec 2023 | $68.0K | $21.2M | −$21.1M |
| Dec 2022 | $0.00 | $33.2M | −$33.2M |
| Dec 2020 | $5.80M | $13.0M | −$7.25M |
| Dec 2019 | $19.8M | $21.6M | −$1.76M |
| Dec 2018 | $23.3M | $23.1M | $203K |
| Dec 2017 | $21.3M | $22.7M | −$1.40M |
| Dec 2016 | $22.3M | $24.6M | −$2.28M |
| Dec 2015 | $24.5M | $31.4M | −$6.89M |
| Dec 2014 | $26.0M | $30.8M | −$4.74M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.